Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference
02 Noviembre 2023 - 6:30AM
Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit
Pharmaceuticals” or “Conduit”), a multi-asset clinical-stage
disease-agnostic life science company delivering an efficient model
for compound development, today announced that its CEO, Dr. David
Tapolczay, and its CFO, Adam Sragovicz, will be attending the 14th
Annual Jefferies London Healthcare Conference, taking place from
Tuesday, November 14 to Thursday, November 16.
About Conduit
Pharmaceuticals
Conduit is a disease-agnostic life science
company delivering an efficient model for compound development.
Conduit both acquires and funds the development of Phase II-ready
assets and then seeks an exit through third-party license deals
following successful clinical trials. Led by a highly experienced
team of pharmaceutical executives, including Dr. David Tapolczay
and Dr. Freda Lewis-Hall, this novel approach is a departure from
the traditional pharma/biotech business model of taking assets
through regulatory approval.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of the federal
securities laws. All statements other than statements of historical
facts contained in this press release, including statements
regarding Conduit’s future results of operations and financial
position, Conduit’s business strategy, prospective product
candidates, product approvals, research and development costs,
timing and likelihood of success, plans and objectives of
management for future operations, future results of current and
anticipated studies and business endeavors with third parties, and
future results of current and anticipated product candidates, are
forward-looking statements. These forward-looking statements
generally are identified by the words “believe,” “project,”
“expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, but not limited to; the
inability to maintain the listing of Conduit’s securities on
Nasdaq; the ability to recognize the anticipated benefits of the
business combination completed in September 2023, which may be
affected by, among other things, competition; the ability of the
combined company to grow and manage growth economically and hire
and retain key employees; the risks that Conduit’s product
candidates in development fail clinical trials or are not approved
by the U.S. Food and Drug Administration or other applicable
authorities on a timely basis or at all; changes in applicable laws
or regulations; the possibility that Conduit may be adversely
affected by other economic, business, and/or competitive factors;
and other risks and uncertainties to be identified in the proxy
statement/prospectus (as amended and supplemented) relating to the
business combination completed in September 2023, including those
under “Risk Factors” therein, and in other filings made by Conduit
with the U.S. Securities and Exchange Commission. Moreover, Conduit
operates in a very competitive and rapidly changing environment.
Because forward-looking statements are inherently subject to risks
and uncertainties, some of which cannot be predicted or quantified
and some of which are beyond Conduit’s control, you should not rely
on these forward-looking statements as predictions of future
events. Forward-looking statements speak only as of the date they
are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and except as required by law, Conduit
assumes no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Conduit gives no assurance that it
will achieve its expectations.
Media:Sean LeousICR
WestwickeSean.Leous@westwicke.com+1.646.866.4012
Investors:Bill BegienConduit Pharmaceuticals
Inc.bb@conduitpharma.com
Conduit Pharmaceuticals (NASDAQ:CDT)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Conduit Pharmaceuticals (NASDAQ:CDT)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024